Schlitzer Martin
Philipps-Universität, Institut für Pharmazeutische Chemie, Marburg, Germany.
Arch Pharm (Weinheim). 2008 Mar;341(3):149-63. doi: 10.1002/ardp.200700184.
Malaria continues to be a potentially fatal threat to almost half of the world's population. In light of this threat, the armory to fight this disease is rather limited. Resistance against the most common and affordable antimalarials is widespread. Only few new drugs are in clinical development, most of them belong to long used classes of antimalarial drugs. This review will concisely cover the drugs which are currently in use, and describe the drug candidates which are in clinical evaluation.
疟疾仍然对世界上近一半的人口构成潜在的致命威胁。鉴于这一威胁,对抗这种疾病的手段相当有限。对最常见且价格亲民的抗疟药物的耐药性普遍存在。目前只有少数新药处于临床开发阶段,其中大多数属于长期使用的抗疟药物类别。本综述将简要介绍目前正在使用的药物,并描述正在进行临床评估的候选药物。